CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

In the article “CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients” by L.A. Lieberman et al.,¹ there are errors in table 1 and figure 3. In table 1, the number of samples reported missed the inclusion of an additional 51 longitudinal NTZ control samples (34 STRATA and 17 non-STRATA) from a serial collection. In figure 3, there is a discrepancy in the assignment of the “at diagnosis” PML samples (red circles). All calculations were performed on the correct data, so neither of these errors affects the conclusions of the manuscript. Corrected versions of both are below. The authors regret the error.

Figure 3.

Table 1.

Patient demographics